Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Muir

Showing results (161-170 of 187) with videos related to

Pageof 19
Sort By:
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Genetics in Medicine Open|May 25, 2026
Evaluating and monitoring liver disease severity in glycogen storage disease type IX: Performance of novel and established clinical scoresAnna Paschall, Rebecca L Koch, Alisha M Mavis, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Gastroenterology|October 12, 2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationMichael Charlton, Edward Gane, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Pageof 19

Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Hepatology (Baltimore, Md.)|June 22, 2010
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infectionAndrew J Muir, Mitchell L Shiffman, Atif Zaman, et al.
Genetics in Medicine Open|May 25, 2026
Evaluating and monitoring liver disease severity in glycogen storage disease type IX: Performance of novel and established clinical scoresAnna Paschall, Rebecca L Koch, Alisha M Mavis, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Journal of Hepatology|November 12, 2018
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trialGideon M Hirschfield, Olivier Chazouillères, Joost P Drenth, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Gastroenterology|October 12, 2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantationMichael Charlton, Edward Gane, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Pageof 19